ZBTB16 (zinc finger and BTB domain containing 16) encodes a transcriptional repressor that functions through recruitment of histone deacetylases to target promoters 1. The protein acts as a probable substrate-recognition component of E3 ubiquitin-ligase complexes mediating proteasomal degradation of target proteins 2. ZBTB16 plays critical roles in multiple developmental and physiological processes: it regulates myeloid maturation, influences cortical neurogenesis via glucocorticoid signaling 3, and maintains endothelial integrity during cardiac aging through suppression of pro-fibrotic signaling 4. The gene also regulates iNKT2 cell differentiation and Th2 immune responses, with elevated expression observed in atherosclerotic plaques 5. Clinically, ZBTB16 alterations associate with several disease contexts: it is recurrently altered in metastatic castration-resistant prostate cancer 6, implicated in acute promyelocytic leukemia variants 7, and identified as a genetic locus associated with polycystic ovary syndrome 8. In HER2-positive breast cancer, ZBTB16 upregulation enhances therapeutic efficacy of combined pyrotinib and chr11 treatment through autophagy induction 9, while in nasopharyngeal carcinoma, ZBTB16 suppression by KDM5B promotes cisplatin resistance 10. These findings establish ZBTB16 as a multifunctional epigenetic regulator with relevance to developmental, metabolic, immunological, and oncological processes.